U.S., Aug. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07125261) titled 'BHV-7000 Responsive Neurostimulation System (RNS) Study' on Aug. 08.
Brief Summary: This is an open label study to assess the biological effect of BHV-7000 on abnormal activity recorded by the RNS System in patients with focal epilepsy implanted with the RNS System. BHV-7000 is a potassium channel activator being evaluated for use in epilepsy. Participants are offered the drug for 4 weeks. Activity during that treatment period is compared to a 90-day retrospective baseline period in which other medications and device settings were stable, and also to a 4-week withdrawal period after treatment is discontinued. The study is open to pa...